Join Growin Stock Community!

Corbus pharmaceuticals holdings, inc.CRBP.US Overview

US StockHealthcare
(No presentation for CRBP)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CRBP AI Insights

CRBP Overall Performance

CRBP AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CRBP Recent Performance

-3.62%

Corbus pharmaceuticals holdings, inc.

0.05%

Avg of Sector

-0.31%

S&P500

CRBP PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CRBP Key Information

CRBP Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CRBP Profile

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Price of CRBP

CRBP FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CRBP Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.39
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
163.32
PB Ratio
1.57
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.39
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
163.32
PB Ratio
1.57
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is CRBP's latest earnings report released?

    The most recent financial report for Corbus pharmaceuticals holdings, inc. (CRBP) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CRBP's short-term business performance and financial health. For the latest updates on CRBP's earnings releases, visit this page regularly.

  • How much debt does CRBP have?

    As of the end of the reporting period, Corbus pharmaceuticals holdings, inc. (CRBP) had total debt of 2.05M, with a debt ratio of 0.02. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CRBP have?

    At the end of the period, Corbus pharmaceuticals holdings, inc. (CRBP) held Total Cash and Cash Equivalents of 27.65M, accounting for 0.25 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is CRBP's EPS continuing to grow?

    According to the past four quarterly reports, Corbus pharmaceuticals holdings, inc. (CRBP)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.9. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CRBP?

    Corbus pharmaceuticals holdings, inc. (CRBP)'s Free Cash Flow (FCF) for the period is -15.55M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 11.53% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.